Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation

Objective— Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N-acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-&agr; (peroxisome proliferator-activated receptors &agr;) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, such as atherosclerosis remain unexplored. Approach and Results— First, the polarization of mouse primary macrophages towards a proinflammatory phenotype was found to reduce N-acyl phosphatidylethanolamine phospholipase D expression and palmitoylethanolamide bioavailability. N-acyl phosphatidylethanolamine phospholipase D expression was progressively downregulated in the aorta of apolipoprotein E deficient (ApoE−/−) mice during atherogenesis. N-acyl phosphatidylethanolamine phospholipase D mRNA levels were also downregulated in unstable human plaques and they positively associated with smooth muscle cell markers and negatively with macrophage markers. Second, ApoE−/− mice were fed a high-fat diet for 4 or 16 weeks and treated with either vehicle or palmitoylethanolamide (3 mg/kg per day, 4 weeks) to study the effects of palmitoylethanolamide on early established and pre-established atherosclerosis. Palmitoylethanolamide treatment reduced plaque size in early atherosclerosis, whereas in pre-established atherosclerosis, palmitoylethanolamide promoted signs of plaque stability as evidenced by reduced macrophage accumulation and necrotic core size, increased collagen deposition and downregulation of M1-type macrophage markers. Mechanistically, we found that palmitoylethanolamide, by activating GPR55, increases the expression of the phagocytosis receptor MerTK (proto-oncogene tyrosine-protein kinase MER) and enhances macrophage efferocytosis, indicative of proresolving properties. Conclusions— The present study demonstrates that palmitoylethanolamide protects against atherosclerosis by promoting an anti-inflammatory and proresolving phenotype of lesional macrophages, representing a new therapeutic approach to resolve arterial inflammation.

[1]  B. Lutz,et al.  Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy , 2018, Front. Mol. Neurosci..

[2]  V. Chair,et al.  Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[3]  S. Cuzzocrea,et al.  Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury , 2017, Pharmacological research.

[4]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[5]  T. Lehtimäki,et al.  Melanocortin 1 Receptor Signaling Regulates Cholesterol Transport in Macrophages , 2017, Circulation.

[6]  M. Bloch,et al.  Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. , 2017, Pain physician.

[7]  S. Petrosino,et al.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations , 2017, British journal of pharmacology.

[8]  M. Daemen,et al.  MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis , 2017, The Journal of clinical investigation.

[9]  M. Perretti,et al.  Aspirin‐triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E−/− mice , 2017, British journal of pharmacology.

[10]  R. Carnuccio,et al.  Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. , 2016, European journal of pharmacology.

[11]  B. He,et al.  Selective activation of CB2 receptor improves efferocytosis in cultured macrophages. , 2016, Life sciences.

[12]  R. Zimmer,et al.  Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. , 2016, Circulation research.

[13]  C. Fowler,et al.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy , 2016, British journal of clinical pharmacology.

[14]  Dajiang J. Liu,et al.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease , 2016, Science.

[15]  B. Lutz,et al.  Myeloid-Specific Deletion of Diacylglycerol Lipase α Inhibits Atherogenesis in ApoE-Deficient Mice , 2016, PloS one.

[16]  B. Lutz,et al.  Extraction and Simultaneous Quantification of Endocannabinoids and Endocannabinoid-Like Lipids in Biological Tissues. , 2016, Methods in molecular biology.

[17]  S. Cuzzocrea,et al.  Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. , 2015, European journal of pharmacology.

[18]  S. Luquet,et al.  Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota , 2015, Nature Communications.

[19]  R. Capasso,et al.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent , 2015, British journal of pharmacology.

[20]  G. Muccioli,et al.  Harnessing the anti-inflammatory potential of palmitoylethanolamide. , 2014, Drug discovery today.

[21]  R. Meli,et al.  Palmitoylethanolamide in CNS health and disease. , 2014, Pharmacological research.

[22]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[23]  M. Daemen,et al.  Atherosclerotic Plaque Destabilization: Mechanisms, Models, and Therapeutic Strategies , 2014, Circulation research.

[24]  T. Lehtimäki,et al.  Association of Neuroimmune Guidance Cue Netrin-1 and Its Chemorepulsive Receptor UNC5B With Atherosclerotic Plaque Expression Signatures and Stability in Human(s): Tampere Vascular Study (TVS) , 2013, Circulation. Cardiovascular genetics.

[25]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[26]  R. Cuomo,et al.  Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation , 2013, Gut.

[27]  T. Lehtimäki,et al.  A comparison of the accuracy of Illumina HumanHT-12 v3 Expression BeadChip and TaqMan qRT-PCR gene expression results in patient samples from the Tampere Vascular Study. , 2013, Atherosclerosis.

[28]  S. Cuzzocrea,et al.  Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice , 2012, Shock.

[29]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[30]  S. Popoff,et al.  The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.

[31]  S. Stepaniants,et al.  A Gene Expression Signature That Classifies Human Atherosclerotic Plaque by Relative Inflammation Status , 2011, Circulation. Cardiovascular genetics.

[32]  Klaus Ley,et al.  Monocyte and macrophage dynamics during atherogenesis. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[33]  P. Sassone-Corsi,et al.  Proinflammatory Stimuli Control N-Acylphosphatidylethanolamine-Specific Phospholipase D Expression in Macrophages , 2011, Molecular Pharmacology.

[34]  T. Bisogno,et al.  Protective role of palmitoylethanolamide in contact allergic dermatitis , 2009, Allergy.

[35]  I. Tabas.  Macrophage death and defective inflammation resolution in atherosclerosis , 2010, Nature Reviews Immunology.

[36]  S. Cuzzocrea,et al.  Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation , 2009, Proceedings of the National Academy of Sciences.

[37]  F. Mach,et al.  Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. , 2009, Atherosclerosis.

[38]  T. Lehtimäki,et al.  ADAM8 and its single nucleotide polymorphism 2662 T/G are associated with advanced atherosclerosis and fatal myocardial infarction: Tampere vascular study , 2009, Annals of medicine.

[39]  D. Schrijvers,et al.  Mertk Receptor Mutation Reduces Efferocytosis Efficiency and Promotes Apoptotic Cell Accumulation and Plaque Necrosis in Atherosclerotic Lesions of Apoe−/− Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[40]  T. Simon,et al.  Defective Mer Receptor Tyrosine Kinase Signaling in Bone Marrow Cells Promotes Apoptotic Cell Accumulation and Accelerates Atherosclerosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  R. Pertwee.  GPR55: a new member of the cannabinoid receptor clan? , 2007, British journal of pharmacology.

[42]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[43]  A. Saghatelian,et al.  Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. , 2006, Biochemistry.

[44]  I. Tabas.  Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis: The Importance of Lesion Stage and Phagocytic Efficiency , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[45]  D. Schrijvers,et al.  Phagocytosis of Apoptotic Cells by Macrophages Is Impaired in Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[46]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[47]  T. V. van Berkel,et al.  Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. , 2004, The American journal of pathology.

[48]  Scott D Covey,et al.  Scavenger Receptor Class B Type I–Mediated Protection Against Atherosclerosis in LDL Receptor–Negative Mice Involves Its Expression in Bone Marrow–Derived Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[49]  J. Fruchart.  Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. , 2001, The American journal of cardiology.

[50]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[51]  D. Rader,et al.  Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[52]  K. Waku,et al.  Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor , 2000, The Journal of Biological Chemistry.

[53]  A. Tall,et al.  Decreased Atherosclerosis in Heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene* , 1999, The Journal of Biological Chemistry.

[54]  A. Tall,et al.  Scavenger Receptor Class B Type I as a Mediator of Cellular Cholesterol Efflux to Lipoproteins and Phospholipid Acceptors* , 1998, The Journal of Biological Chemistry.

[55]  L. Petrelli,et al.  N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. , 1996, European journal of pharmacology.

[56]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.